Research programme: T-cell therapies- Triumvira

Drug Profile

Research programme: T-cell therapies- Triumvira

Alternative Names: CD19 TAC; CD19-TAC01; TAC#921; TAC-921

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Triumvira
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical B cell lymphoma; Leukaemia; Multiple myeloma; Ovarian cancer
  • Research Solid tumours

Most Recent Events

  • 02 May 2018 Triumvira Immunologics enters into a strategic relationship for GMP Manufacturing of T-cell therapies with Centre for Commercialisation of Cancer Immunotherapy (C3i) and market-licenses CD19 TAC to C3i in Canada
  • 22 Mar 2018 Triumvira plans a phase I/II trial of TAC 921 for Diffuse large B-cell lymphoma (Second-line therapy or greater), in the first quarter of 2019
  • 28 Jun 2016 Preclinical trials in Ovarian cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top